A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and ...

As the authors reported in Radiology Case Reports, the patient had no history of cancer and had no pain, weakness, numbness, ...

A multiple myeloma diagnosis is a life event that can be overwhelming. Get trusted information for every step of your journey. Multiple myeloma can be tricky. That’s because it sometimes has no ...

New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma ...

During a live event, Naresh Bumma, MD, discussed CRS, oral and skin toxicities, and low discontinuation rates with ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual ...

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory ...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...